NASDAQ:NUVL Nuvalent (NUVL) Stock Price, News & Analysis $97.10 +4.58 (+4.95%) As of 02:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvalent Stock (NASDAQ:NUVL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvalent alerts:Sign Up Key Stats Today's Range$91.72▼$97.9350-Day Range$73.24▼$92.5252-Week Range$55.53▼$104.44Volume453,009 shsAverage Volume514,448 shsMarket Capitalization$7.00 billionP/E RatioN/ADividend YieldN/APrice Target$120.00Consensus RatingModerate Buy Company Overview Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets. Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations. These assets are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe, with early data demonstrating favorable safety profiles and preliminary signs of clinical activity in patients with RET-driven and KRAS-mutant solid tumors. In addition to these core programs, Nuvalent continues to leverage its structure-based approach to advance discovery efforts and expand its portfolio into other oncogenic targets. The company conducts its operations primarily in North America, supported by strategic collaborations and investigator-led studies in international research centers. Under the leadership of President and Chief Executive Officer Bill Haney, Nuvalent has assembled a management team with extensive experience in oncology drug development, regulatory affairs and commercial planning. The organization remains committed to translating cutting-edge science into precision medicines that address unmet needs in cancer therapy.AI Generated. May Contain Errors. Read More Nuvalent Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreNUVL MarketRank™: Nuvalent scored higher than 53% of companies evaluated by MarketBeat, and ranked 457th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNuvalent has a consensus price target of $120.00, representing about 24.3% upside from its current price of $96.53.Amount of Analyst CoverageNuvalent has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nuvalent's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nuvalent are expected to decrease in the coming year, from ($3.86) to ($4.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -19.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -19.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 6.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvalent's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.85% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvalent has recently decreased by 0.75%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.85% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvalent has recently decreased by 0.75%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News Sentiment0.18 News SentimentNuvalent has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 35 news articles for Nuvalent this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for NUVL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Nuvalent to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,298,129.00 in company stock.Percentage Held by Insiders10.20% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvalent's insider trading history. Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NUVL Stock News HeadlinesAlexandra Balcom Sells 1,683 Shares of Nuvalent (NASDAQ:NUVL) StockOctober 18 at 5:58 AM | insidertrades.comNuvalent (NASDAQ:NUVL) Insider Sells $208,702.74 in StockOctober 16, 2025 | insidertrades.comTesla to LEAVE the car market?Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corporate history. Tesla insiders are preparing for a dramatic new product launch – not driverless cars – that could change everything. You're running out of time to prepare.October 20 at 2:00 AM | Altimetry (Ad)Nuvalent (NASDAQ:NUVL) CFO Sells $645,055.88 in StockOctober 2, 2025 | insidertrades.comNuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trialOctober 19 at 11:23 PM | msn.comNuvalent (NASDAQ:NUVL) Earns Buy Rating from Analysts at Stifel NicolausOctober 19 at 2:53 AM | americanbankingnews.comNuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025October 18 at 6:00 AM | prnewswire.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 18 at 2:09 AM | americanbankingnews.comSee More Headlines NUVL Stock Analysis - Frequently Asked Questions How have NUVL shares performed this year? Nuvalent's stock was trading at $78.28 on January 1st, 2025. Since then, NUVL stock has increased by 23.3% and is now trading at $96.53. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) announced its earnings results on Thursday, August, 7th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by $0.04. When did Nuvalent IPO? Nuvalent (NUVL) raised $151 million in an initial public offering on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Nuvalent's top institutional investors include Voya Investment Management LLC (0.19%) and CWM LLC. Insiders that own company stock include Andrew A F Hack, James Richard Porter, Matthew Shair, Henry E Pelish, Alexandra Balcom, Deborah Ann Miller, Darlene Noci, Christopher Durant Turner and Emily Conley. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvalent own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvalent investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/07/2025Today10/20/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NUVL CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees40Year Founded2017Price Target and Rating Average Price Target for Nuvalent$120.00 High Price Target$140.00 Low Price Target$100.00 Potential Upside/Downside+27.4%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($4.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$260.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.58% Return on Assets-30.14% Debt Debt-to-Equity RatioN/A Current Ratio13.57 Quick Ratio13.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.99 per share Price / Book6.28Miscellaneous Outstanding Shares72,110,000Free Float64,750,000Market Cap$6.79 billion OptionableOptionable Beta1.30 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:NUVL) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.